Late-Breaking Abstract Session

Join this session to hear the latest scientific advances in hepatology. Presentations will be followed by a live moderated Q&A

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of the Efficacy and Safety of Namodenoson (CF102), an A3 Adenozine Receptor, (A3AR) Agonist, in Treating Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alconolic Steatohepatitis (NASH) Presenting Author Rifaat Safadi
• Safety and Efficacy of Combination Therapies Including Semaglutide, Cilofexor, and Firsocostat in Patients with NASH Presenting Author Naim Alkhouri
• Aldafermin (NGM282) Produces Greated Anti-Fibrotic Response in Patients with NonAlcoholics Steatohepatitis and Advanced Fibrosis Presenting Author Guy Neff
• Efficacy and Safety of Odevixibat, an Illeal Bile Acid Transporter Inhibitor, in Children with Progressive Familial Intrahepatic Choilestasis Types 1 and 2: Results from PEDFIC Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial Presenting Author Richard J. Thompson
• Preliminary Analysis of Itch and Imagine II - Outcome of Long-Term Administration of Maralixibat in Children with Alagille Syndrome Presenting Author Benjamin L. Shneider
• Microfibril Associate Protein 4 (Mfap4) as a Potential Regulator of Liver Regeneration and Disease Presenting Author Viktoriia Iakovleva